News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn spinout and I-Corps participant NeuroFlow raises $25 million growth round, doubles headcount and expands into Center City office
The funding will help Neuroflow, a Philadelphia-based mental health startup, make greater investments in research and development, expand its technology platform and increase headcount.
Philadelphia gene therapy company Passage Bio names former Novartis executive as new CEO
Philadelphia gene therapy company Passage Bio appointed Dr. Will Chou, former Novartis executive, as its new CEO.
Penn Spinout and I-Corps Participant Innervace Raises $40 Million for Parkinson’s Disease Research
The funds will allow Innervace to advance their platform and lead asset in Parkinson’s disease, which aims to reconstruct the neuronal circuitry that is lost in Parkinson's patients.
The Power of Pennovation Works: Research and Development
In November, in recognition of the 5th year anniversary of Pennovation Works, the Pennovation Center hosted The Power of Pennovation Works: Research and Development panel.
Philadelphia Ranks Second in New Study Comparing U.S. Cell and Gene Therapy Hubs
Philadelphia ranks second in a newly released study comparing 14 U.S. cell and gene therapy hubs in five key categories.
Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.
Penn Ranks Number 15 on Report of Top 100 Worldwide Universities Granted U.S. Utility Patents in 2021
The National Academy of Inventors & the Intellectual Property Owners Association ranked Penn in the Top 100 Worldwide Universities Granted U.S. Utility Patents in 2021.
Weissman Lab is Working on New Type of Vaccines to Protect Against All Coronaviruses
The Weissman Lab is working towards developing vaccines that not only target multiple COVID variants, but also multiple types of coronaviruses.
PCI Fellows Enjoy First In-Person Meeting of the Year
On September 19, the PCI Fellows got together for their first in-person meeting since the cohort began in April.